Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

Inclusion Criteria: * HIV-1 Infection * HIV-1 RNA \<50 copies/mL on all measurements within 48 weeks prior to study entry while on any DHHS recommended or alternative three-drug antiretroviral regimen. (A history of switching for simplification and/or tolerability is allowed. At least two measurements within the previous 48 weeks are required prior to study screening.) * No history of virologic failure, defined as consecutive HIV RNA \> 50 copies/mL after 12 months of initiating ART. An isolated (non-consecutive) HIV RNA \> 50 copies/mL (but less than 400 copies/mL) is permitted after 12 months of initiating ART but not in the 48-week window prior to study entry. * Screening plasma HIV RNA \< 20 copies/mL using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test V2.0, obtained within 45 days prior to study entry * Nadir CD4 count \>200 cells/mm * Pretreatment genotype documenting no mutations in the protease or reverse transcriptase genes * No known resistance to integrase inhibitors * Laboratory values obtained within 45 days prior to study entry: ANC \>750 Hemoglobin \>10 g/dL Platelets \>50,000 Calculated creatinine clearance (CrCl) \>50 mL/min * Negative serum or urine pregnancy test * Men and women age greater or equal to 18 years. * Ability to continue current regimen (i.e, have uninterrupted access) * No evidence of chronic hepatitis B Exclusion Criteria: * Serious illness or AIDS-related complication within 21 days of screening requiring systemic treatment and/or hospitalization * Treatment within 30 days prior to study entry with immune modulators * Vaccination within 7 days * Active HCV treatment or anticipated need for treatment within study period. (HCV infection alone is not exclusionary) * Unstable liver disease or severe hepatic impairment * Known allergy or hypersensitivity to DTG or lamivudine. * Active drug or alcohol use or dependence that could interfere with adherence to study requirements * ALT (alanine aminotransferase) \>5 x ULN (upper limit of normal) OR ALT \>3 x ULN and total bilirubin \>1.5 x ULN (with 35% direct bilirubin)